Fig. 3From: Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patientsCost-effectiveness plane plotting incremental QALY and costs comparing NGS (strategy 3) vs sequential tests (strategy 2)Back to article page